These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 18243402)

  • 1. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
    Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
    Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
    Takano T; Ohe Y; Sakamoto H; Tsuta K; Matsuno Y; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Shibata T; Sakiyama T; Yoshida T; Tamura T
    J Clin Oncol; 2005 Oct; 23(28):6829-37. PubMed ID: 15998907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
    J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
    Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
    J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
    Endo K; Sasaki H; Yano M; Kobayashi Y; Yukiue H; Haneda H; Suzuki E; Kawano O; Fujii Y
    Oncol Rep; 2006 Sep; 16(3):533-41. PubMed ID: 16865253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
    Dziadziuszko R; Witta SE; Cappuzzo F; Park S; Tanaka K; Danenberg PV; Barón AE; Crino L; Franklin WA; Bunn PA; Varella-Garcia M; Danenberg KD; Hirsch FR
    Clin Cancer Res; 2006 May; 12(10):3078-84. PubMed ID: 16707605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
    Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N
    Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
    J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
    Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC
    Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
    Cappuzzo F; Ligorio C; Jänne PA; Toschi L; Rossi E; Trisolini R; Paioli D; Holmes AJ; Magrini E; Finocchiaro G; Bartolini S; Cancellieri A; Ciardiello F; Patelli M; Crino L; Varella-Garcia M
    J Clin Oncol; 2007 Jun; 25(16):2248-55. PubMed ID: 17538169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
    Chen X; Li W; Hu X; Geng Y; Wang R; Yin Y; Shu Y
    Biomed Pharmacother; 2011 Dec; 65(8):542-6. PubMed ID: 21840160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
    Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC
    Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
    Pugh TJ; Bebb G; Barclay L; Sutcliffe M; Fee J; Salski C; O'Connor R; Ho C; Murray N; Melosky B; English J; Vielkind J; Horsman D; Laskin JJ; Marra MA
    BMC Cancer; 2007 Jul; 7():128. PubMed ID: 17626639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.